Erythema nodosum-like panniculitis as a false-positive 18F-FDG PET/CT in advanced melanoma treated with dabrafenib and trametinib

Clinical Nuclear Medicine

Volumn 42, Issue 1, 2016, Pages 44-46

  Martínez Rodríguez, Isabel ^a   García Castaño, Almudena ^a   Quirce, Remedios ^a   Jiménez Bonilla, Julio ^a   Banzo, Ignacio ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

18F FDG PET CT; Dabrafenib; Erythema nodosum; Melanoma; Panniculitis; Trametinib

Indexed keywords

B RAF KINASE; DABRAFENIB; FLUORODEOXYGLUCOSE F 18; TRAMETINIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; CASE REPORT; CLINICAL ARTICLE; ERYTHEMA NODOSUM; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPHADENOPATHY; MELANOMA; METABOLISM; PANNICULITIS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; SKIN BIOPSY; SKIN DEFECT; SOFT TISSUE METASTASIS; SUBCUTANEOUS NODULE; DIAGNOSTIC IMAGING; PATHOLOGY;

ADULT; ANTINEOPLASTIC AGENTS; ERYTHEMA NODOSUM; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMIDAZOLES; MELANOMA; OXIMES; PANNICULITIS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PYRIDONES; PYRIMIDINONES; RADIOPHARMACEUTICALS;

EID: 85027943774     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001448     Document Type: Article

References (13)

1. Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol. 2009;4:551-579.
2. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385-394.
3. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-1703.
4. Baudy AR, Dogan T, Flores-Mercado JE, et al. FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res. 2012;2:22.
5. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutatedmetastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358-365.
6. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444-451.
7. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30-39.
8. Long GV, Weber JS, Infante JR, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016;34:871-878.
9. Carlos G, Anforth R, Clements A, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151:1103-1109.
10. 18F-FDG PET/CTresponse to BRAFandMEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun. 2016;37:122-128.
11. Galliker NA, Murer C, Kamarashev J, et al. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. Eur J Dermatol. 2015;25:177-180.
12. Mossner R, Zimmer L, Berking C, et al. Erythema nodosum-like lesions during BRAF inhibitor therapy: report on 16 new cases and review of the literature. J Eur Acad Dermatol Venereol. 2015;29:1797-1806.
13. 18F-FDG PET/CT. Clin Nucl Med. 2016;41:e149-e151.